Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2008019303) PYRIDAZINONYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2008/019303 International Application No.: PCT/US2007/075146
Publication Date: 14.02.2008 International Filing Date: 03.08.2007
IPC:
A61K 38/12 (2006.01) ,C07K 5/12 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12
Cyclic peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
5
Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04
containing only normal peptide links
12
Cyclic peptides
Applicants:
ENANTA PHARMACEUTICALS, INC. [US/US]; 500 Arsenal Street Watertown, MA 02472, US (AllExceptUS)
MOORE, Joel, D. [US/US]; US (UsOnly)
TANG, Datong [CN/US]; US (UsOnly)
OR, Yat, Sun [US/US]; US (UsOnly)
WANG, Zhe [US/US]; US (UsOnly)
Inventors:
MOORE, Joel, D.; US
TANG, Datong; US
OR, Yat, Sun; US
WANG, Zhe; US
Agent:
NAKAJIMA, Suanne ; Elmore Patent Law Group, P.C. 515 Groton Road, Unit 1 R Westford, MA 01886, US
Priority Data:
11/499,84404.08.2006US
11/832,89302.08.2007US
Title (EN) PYRIDAZINONYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
(FR) INHIBITEURS DE SÉRINE PROTÉASES DE L'HÉPATITE C MACROCYCLIQUES DE TYPE PYRIDAZINONYLE
Abstract:
(EN) The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
(FR) La présente invention concerne des composés de formule I ou leurs sels, esters ou prodrogues pharmaceutiquement acceptables, qui inhibent l'activité des sérine protéases, en particulier l'activité de la protéase NS3-NS4A du virus de l'hépatite C (VHC). En conséquence, les composés de la présente invention perturbent le cycle vital du virus de l'hépatite C et ils sont également utiles comme agents antiviraux. La présente invention concerne en outre des compositions pharmaceutiques comprenant les composés ci-dessus, destinées à être administrées à un sujet atteint d'une infection par le VHC. L'invention concerne également des procédés de traitement d'une infection par le VHC chez un sujet en lui administrant une composition pharmaceutique comprenant un composé de la présente invention.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)